Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 9, Issue 6, 2006, Pages 519-524

  Shi, Meiqi ^a   Gao, Changming ^a   Wu, Jianzhong ^a   Feng, Jifeng ^a   Cao, Haixia ^a   Lu, Jianwei ^a   Xu, Lin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Chemotherapy; Genotype; Methylenetetrahydrofolate reductase; Non small cell lung cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; LOBAPLATIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; PLATINUM COMPLEX; VINDESINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33846031126     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gao CM, Wu JZ, Ding JH, et al. Polymorphisms of methylenetetrahydrofolate reductase C677T and the risk of stomach cancer. Chin J Epidemiol, 2002, 23(4):289-292.
2. Gao CM, Toshiro T, Wu JZ, et al. A case-control study on the polymorphisms of methylenetetrahydrofolate reductase 1298A→C and susceptibility of esophageal cancer. Chin J Epidemiol, 2004, 25 (4):341-345.
3. Satoh A, Toyota M, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res, 2003, 63(24):8606-8613.
4. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med, 2003, 9(5):568-574.
5. Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res, 2004, 64(9):2994-2997.
6. Rothfuss A, Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol Cell Biol, 2004, 24(1):123-134.
7. Gao CM, Lu JW, Toshiro T, et al. Polymorphism of methylenetetrahydrofolate reductase and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. Chin J Epidemiol, 2004, 25 (12):1054-1058.
8. Lu JW, Gao CM, Wu JZ, et al. Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-Fluorouracil in gastric carcinoma. Chin J Cancer, 2004, 23(8): 958-962.
9. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 1995, 10(1):111-113.
10. Stern LL, Mason JB, Selhub J, et al. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev, 2000, 9(8):849-853.
11. Zhang TZ, Xu GW ed. Oncology (Volume 2). Tianjin: Scientific and Technical Publication, 1996, 1629.
12. Wang SM, Liu XJ, Wu AH, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase and clinical significance. Section of Genetics, Forei Med Sci, 2005, 28(1):29-32.
13. Qian L ed. Basic and clinial oncology. Beijing: Chinese Medical Scientific and Technical Publication, 1994, 322.
14. Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene, 2004, 23(4):1000-1004.
15. Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs, 1999, 22(2):176-183.
16. Alberola V, Sarries C, Rosell R, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer, 2004, 5(6):360-365.